STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
STK11 aberrations hampered the mOS of nsq NSCLC patients treated with first-line ICI or CT-ICI. The negative prognostic impact seems to be unrelated to ICI administration.
Authors
- Giulia Venturi (ORCID: https://orcid.org/0000-0002-1624-8946)
- Claudia Parisi (ORCID: https://orcid.org/0000-0002-6259-8234)
- Francesco Gelsomino (ORCID: https://orcid.org/0000-0002-9204-1728)
- Elisa Gruppioni (ORCID: https://orcid.org/0000-0002-4334-6170)
- Andrea Ardizzoni (ORCID: https://orcid.org/0000-0003-2678-0714)
- Valentina Favorito (ORCID: https://orcid.org/0009-0001-5282-260X)
- Dario de Biase (ORCID: https://orcid.org/0000-0002-0609-8817)
- Filippo Gustavo Dall’Olio (ORCID: https://orcid.org/0000-0003-0903-6109)
- Thais Maloberti (ORCID: https://orcid.org/0000-0002-8306-4653)
- Ambrogio Gagliano
- Alessandro Di Federico (ORCID: https://orcid.org/0000-0001-8877-4315)
- Barbara Melotti (ORCID: https://orcid.org/0000-0003-1041-391X)
- Federico Zacchini (ORCID: https://orcid.org/0000-0002-6038-1779)
- Francesca Sperandi (ORCID: https://orcid.org/0000-0002-1581-3456)
- Andrea De Giglio (ORCID: https://orcid.org/0000-0002-0731-5721)
- Annalisa Altimari (ORCID: https://orcid.org/0000-0001-9944-2455)
- Giovanni Tallini (ORCID: https://orcid.org/0000-0003-0113-6682)
- Lorenzo Montanaro (ORCID: https://orcid.org/0000-0001-9776-9518)
- Ilaria Ricciotti
Institutions
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Azienda USL di Bologna (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Lung Cancer
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1016/j.lungcan.2024.108058
- Citations
- 16
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 6.80
Funders
- European Commission
- Ministero dell’Istruzione, dell’Università e della Ricerca